NCT05199337 2024-09-19Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) AmyloidosisK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.Phase 1/2 Completed18 enrolled